MARKET

KLRA

KLRA

Kailera Therapeutics
NASDAQ
22.88
-0.07
-0.28%
Opening 13:59 05/29 EDT
OPEN
23.00
PREV CLOSE
22.94
HIGH
24.19
LOW
22.81
VOLUME
245.28K
TURNOVER
--
52 WEEK HIGH
28.23
52 WEEK LOW
19.01
MARKET CAP
2.96B
P/E (TTM)
-18.9929
1D
5D
1M
3M
1Y
5Y
1D
Kailera Therapeutics CEO Ron Renaud presents at Jefferies Global Healthcare Conference
PUBT · 21h ago
Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA)
TipRanks · 1d ago
Analyst Initiates Buy on Kailera, Citing Diversified GLP‑1 Pipeline and Pivotal 2027 Obesity Data Catalysts
TipRanks · 2d ago
TD Cowen Reaffirms Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)
TipRanks · 2d ago
Kailera Therapeutics Q1 EPS $(3.65) Misses $(0.68) Estimate as R&D Spend Jumps to $70.9M
Benzinga · 2d ago
Kailera Therapeutics, Inc. reports Q1 results
Seeking Alpha · 2d ago
Kailera Q1 FY26 net loss more than quadruples to $78.87 million
PUBT · 2d ago
KAILERA THERAPEUTICS INC - Q1 NET LOSS $78.9 MLN
Reuters · 2d ago
More
About KLRA
Kailera Therapeutics Inc is a United States-based company. The Company is a clinical-stage biopharmaceutical company developing a broad and advanced therapeutic pipeline that is poised to deliver differentiated treatment options for obesity and related conditions. Its pipeline consists of clinical- and preclinical-stage programs with injectable peptides, oral peptides, and an oral small molecule.

Webull offers Kailera Therapeutics Inc stock information, including NASDAQ: KLRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KLRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KLRA stock methods without spending real money on the virtual paper trading platform.